Concepedia

Author

J.A. van Dongen

The Netherlands Cancer Institute

Also Known As

J A van Dongen, J. A. Van Dongen, J. A. van Dongen, J.A van Dongen, J.A. Van Dongen, J.A. van Dongen, JA van Dongen, Joop A. van Dongen

55

Publications

3.3K

Citations

19

H-Index

36

Concepts

All Affiliations

The Netherlands Cancer InstituteRotterdam University of Applied SciencesOncode InstituteEuropean Organisation for Research and Treatment of CancerUniversitair Ziekenhuis Leuven
JV

About

J.A. van Dongen is an author at The Netherlands Cancer Institute specializing in medicine, breast cancer, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

12

988

2

Health Sciences

1

1

14

3

Public Health

1

1

10

4

Emergency Medicine

1

1

29

5

Epidemiology

1

1

10

J.A. van Dongen

×

20

Publications

3.1K

Citations

17

H-Index

YearCitations

Long-Term Results of a Randomized Trial Comparing Breast-Conserving Therapy With Mastectomy: European Organization for Research and Treatment of Cancer 10801 Trial

J.A. van Dongen

JNCI Journal of the National Cancer Institute

2000

1.3K

Differences in Risk Factors for Local and Distant Recurrence After Breast-Conserving Therapy or Mastectomy for Stage I and II Breast Cancer: Pooled Results of Two Large European Randomized Trials

Adri C. Voogd, Maja Nielsen, Johannes L. Peterse,

Journal of Clinical Oncology

2001

560

Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer

J.A. van Dongen, Harry Bartelink, Ian S. Fentiman,

European Journal of Cancer

1992

271

Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM)

Geertjan van Tienhoven, Adri C. Voogd, Johannes L. Peterse,

European Journal of Cancer

1999

216

The Impact of tumor size and histology on local control after breast-conserving therapy

Harry Bartelink, Jacques Borger, J.A. van Dongen,

Radiotherapy and Oncology

1988

212

Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival.

Astrid Morris, Robert D. Morris, J. F. Wilson,

PubMed

1997

161

Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease?

Liesbeth Bergman, J.A. van Dongen, B van Ooijen,

Breast Cancer Research and Treatment

1995

58

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb

JM Klaase, B.B.R. Kroon, J. H. Beijnen,

British Journal of Cancer

1994

51

Systemic toxicity after isolated limb perfusion with melphalan for melanoma

Eric J.A. Sonneveld, Bart C. Vrouenraets, Bert N. van Geel,

European Journal of Surgical Oncology

1996

42

Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb

Bin B. R. Kroon, Joost M. Klaase, Bert N. van Geel,

European Journal of Cancer

1993

40

Page 1